Methods of treating cancer by administering anti-GPR49 antibodies
Described herein are antibodies against GPR49 and uses of such antibodies. Various aspects relate to monoclonal, humanized, or fully human antibodies against GPR49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies.
1. A method of treating a cancer comprising a solid tumor in a mammal, comprising administering to the mammal a therapeutic amount of a monoclonal antibody that binds to G-Protein Coupled Receptor 49 (GPR49) polypeptide and cross-reacts with G-Protein Coupled Receptor 48 (GPR48), wherein the therapeutic amount is sufficient to treat the cancer.
2. The method of claim 1 , wherein the antibody does not cross-react with Leucine-rich Repeat Containing G-Protein Coupled Receptor 6 (LGR6) at a K d of less than 10 −9 M.
3. The method of claim 2 , wherein the antibody does not cross-react with LGR6 at a K d of less than 10 −6 M.
4. The method of claim 3 , wherein the antibody does not cross-react with LGR6 at a K d of less than 10 −3 M.
5. The method of claim 1 , wherein the antibody cross-reacts with GPR48 at a K d of less than 10 −6 .
6. The method of claim 5 , wherein the antibody cross-reacts with GPR48 at a K d of less than 10 −9 .
7. The method of claim 1 , wherein the GPR49 polypeptide has the amino acid sequence of SEQ ID NO: 1.
8. The method of claim 1 , wherein the antibody is an IgG class antibody.
9. The method of claim 2 , wherein the antibody is an IgG1 class antibody.
10. The method of claim 2 , wherein the antibody is a human antibody.
11. The method of claim 2 , wherein the antibody is a mouse antibody.
12. The method of claim 1 , wherein the antibody binds GPR49 with a K d of less than 5×10 −9 M.
13. The method of claim 1 , wherein the antibody binds GPR49 with a K d of less than 10 −9 M.
14. The method of claim 1 , wherein the antibody binds GPR49 with a K d of less than 10 −10 M.
15. The method of claim 1 , wherein the antibody binds to GPR49 polypeptide with a K d of less than 1×10 −12 M.
16. The method of claim 1 , wherein the cancer is colon cancer.
17. The method of claim 1 , wherein the cancer comprises colon cancer stem cells.
18. The method of claim 1 , further comprising administering irinotecan.
19. The method of claim 1 , wherein the cancer comprises a mutation in a gene known to cause cancer selected from the group consisting of K-Ras, PI3K, PTEN, H-Ras, APC, TP53, FGFR2, VANGL2, STK11, JAK2, and RB1.
20. The method of claim 1 , wherein the cancer comprises a colon adenocarcinoma.
21. The method of claim 1 , wherein the monoclonal antibody specifically binds to a polypeptide comprising SEQ ID NO:03.
22. The method of claim 1 , wherein the monoclonal antibody comprises a Fab fragment obtained from an in vitro expression library.